These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29530550)

  • 1. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    Smith PA; Schmid C; Zurbruegg S; Jivkov M; Doelemeyer A; Theil D; Dubost V; Beckmann N
    J Neuroimmunol; 2018 May; 318():103-113. PubMed ID: 29530550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.
    Bonfiglio T; Olivero G; Merega E; Di Prisco S; Padolecchia C; Grilli M; Milanese M; Di Cesare Mannelli L; Ghelardini C; Bonanno G; Marchi M; Pittaluga A
    PLoS One; 2017; 12(1):e0170825. PubMed ID: 28125677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
    Zhang J; Zhang ZG; Li Y; Ding X; Shang X; Lu M; Elias SB; Chopp M
    Neurobiol Dis; 2015 Apr; 76():57-66. PubMed ID: 25680941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.
    Groh J; Berve K; Martini R
    Mol Ther; 2017 Aug; 25(8):1889-1899. PubMed ID: 28506594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
    J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
    Rossi S; Lo Giudice T; De Chiara V; Musella A; Studer V; Motta C; Bernardi G; Martino G; Furlan R; Martorana A; Centonze D
    Br J Pharmacol; 2012 Feb; 165(4):861-9. PubMed ID: 21740406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
    Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
    Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
    Hou H; Cao R; Miao J; Sun Y; Liu X; Song X; Guo L
    Int Immunopharmacol; 2016 Jan; 30():171-178. PubMed ID: 26632437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
    Camacho-Toledano C; Machín-Díaz I; Calahorra L; Cabañas-Cotillas M; Otaegui D; Castillo-Triviño T; Villar LM; Costa-Frossard L; Comabella M; Midaglia L; García-Domínguez JM; García-Arocha J; Ortega MC; Clemente D
    J Neuroinflammation; 2022 Nov; 19(1):277. PubMed ID: 36403026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental Autoimmune Encephalomyelitis (EAE)-Induced Elevated Expression of the E1 Isoform of Methyl CpG Binding Protein 2 (MeCP2E1): Implications in Multiple Sclerosis (MS)-Induced Neurological Disability and Associated Myelin Damage.
    Khorshid Ahmad T; Zhou T; AlTaweel K; Cortes C; Lillico R; Lakowski TM; Gozda K; Namaka MP
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28604632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis.
    Kassis I; Ben-Zwi M; Petrou P; Halimi M; Karussis D
    Immunol Lett; 2021 May; 233():11-19. PubMed ID: 33676976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential brain and spinal cord cytokine and BDNF levels in experimental autoimmune encephalomyelitis are modulated by prior and regular exercise.
    Bernardes D; Oliveira-Lima OC; Silva TV; Faraco CC; Leite HR; Juliano MA; Santos DM; Bethea JR; Brambilla R; Orian JM; Arantes RM; Carvalho-Tavares J
    J Neuroimmunol; 2013 Nov; 264(1-2):24-34. PubMed ID: 24054000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
    Airas L; Dickens AM; Elo P; Marjamäki P; Johansson J; Eskola O; Jones PA; Trigg W; Solin O; Haaparanta-Solin M; Anthony DC; Rinne J
    J Nucl Med; 2015 Feb; 56(2):305-10. PubMed ID: 25572093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis.
    Vállez García D; Doorduin J; de Paula Faria D; Dierckx RAJO; de Vries EFJ
    J Neuroimmune Pharmacol; 2017 Sep; 12(3):521-530. PubMed ID: 28361437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis.
    Golan M; Mausner-Fainberg K; Ibrahim B; Benhamou M; Wilf-Yarkoni A; Kolb H; Regev K; Karni A
    CNS Drugs; 2019 Dec; 33(12):1229-1237. PubMed ID: 31713782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    Kasheke GDS; Holman SP; Robertson GS
    J Neuroimmunol; 2022 Sep; 370():577926. PubMed ID: 35863299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
    de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ
    Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice.
    Zhu D; Liu M; Yang Y; Ma L; Jiang Y; Zhou L; Huang Q; Pi R; Chen X
    J Neurosci Res; 2014 Sep; 92(9):1217-26. PubMed ID: 24798871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral drugs for the treatment of multiple sclerosis.
    Chard D; Trip A; Chataway J
    Br J Hosp Med (Lond); 2016 Sep; 77(9):502-3. PubMed ID: 27640651
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
    Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
    Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.